Healthcare -
Biotechnology - NASDAQ - US
$ 5.94
-5.71 %
$ 321 M
Market Cap
-3.6
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
Stoke Therapeutics, Inc.
| Current Assets | 233 M |
| Cash & Short-Term Investments | 217 M |
| Receivables | 700 K |
| Other Current Assets | 15.2 M |
| Non-Current Assets | 38.8 M |
| Long-Term Investments | 0 |
| PP&E | 8.25 M |
| Other Non-Current Assets | 30.5 M |
| Current Liabilities | 40.1 M |
| Accounts Payable | 2.5 M |
| Short-Term Debt | 2.32 M |
| Other Current Liabilities | 35.2 M |
| Non-Current Liabilities | 2.48 M |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 2.48 M |
EFFICIENCY
Earnings Waterfall
Stoke Therapeutics, Inc.
| Revenue | 36.6 M |
| Cost Of Revenue | 0 |
| Gross Profit | 36.6 M |
| Operating Expenses | 138 M |
| Operating Income | -101 M |
| Other Expenses | -12.4 M |
| Net Income | -89 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Stoke Therapeutics, Inc.
| Net Income | -89 M |
| Depreciation & Amortization | 2.18 M |
| Capital Expenditures | -203 K |
| Stock-Based Compensation | 27.5 M |
| Change in Working Capital | -28.1 M |
| Others | -30.6 M |
| Free Cash Flow | -87.1 M |
Wall Street Analysts Price Targets
Stoke Therapeutics, Inc.
Wall Street analysts predict an average 1-year price target for STOK of $24.3 , with forecasts ranging from
a
low of
$18 to a high of $35 .
STOK Lowest Price Target
Wall Street Target
18 USD
203.03%
STOK Average Price Target
Wall Street Target
24.3 USD
309.65%
STOK Highest Price Target
Wall Street Target
35 USD
489.23%
4. DIVIDEND
ANALYSIS
STOK does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Stoke Therapeutics, Inc.
Sold
0-3 MONTHS
261 K USD 3
3-6 MONTHS
23.9 M USD 4
6-9 MONTHS
27.6 M USD 2
9-12 MONTHS
44.7 M USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Stoke Therapeutics Stock Slips as CEO Steps Down
Shares of Stoke Therapeutics (STOK) slipped Tuesday as the drugmaker said its CEO Dr. Edward Kaye is stepping down from his role.
investopedia.com
- 2 weeks ago
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.60 per share a year ago.
zacks.com
- 2 weeks ago
Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the full year ended December 31, 2024 and provided business updates. “Recent milestones – including Breakt.
businesswire.com
- 2 weeks ago
Stoke Therapeutics Announces CEO Transition
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today the Company announced that Edward M. Kaye, M.D., has decided to step down from his role as Chief Executive Officer effective as of March 19, 2025. To.
businesswire.com
- 2 weeks ago
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Stoke Therapeutics (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
- 2 weeks ago
Stoke Therapeutics to Present at Upcoming Investor Conferences in March
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that management will present at the following upcoming investor conferences: TD Cowen 45th Annual Healthcare Conference Date: Wednesday, March 5, 2025 Time: 9:50 a.m. ET Leerink Partners Global Healthcare Conference Date: Monday, March 10, 2025 Time: 10:40 a.m. ET Live webcasts of each ev.
businesswire.com
- 1 month ago
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights Collaboration broadens Biogen's rare disease pipeline and leverages global expertise commercializing high-value, disease-modifying medicines for rare genetic diseases Pivotal Phase 3 EMPEROR study of zorevunersen on track to initiate in Q2 2025 with an anticipated readout in 2H 2027 Stoke to receive $165M upfront, shared development costs and is eligible to receive up to $385M in milestones as well as royalties CAMBRIDGE, Mass. and BEDFORD, Mass.
globenewswire.com
- 1 month ago
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
CAMBRIDGE, Mass. & BEDFORD, Mass.--(BUSINESS WIRE)--Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for the development and commercialization of zorevunersen, a potential first-in-class disease modifying medicine in development for the treatment of Dravet syndrome, in all territories outside the United States, Canada, and Mexico. Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying c.
businesswire.com
- 1 month ago
Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer
Stoke Therapeutics' RNA-based treatments for severe neurological and ophthalmic disorders, particularly zorevunersen for Dravet syndrome, show potential for long-term value beyond a single drug. Financials reveal high R&D spending and cash burn, but revenue growth from Acadia Pharmaceuticals collaboration suggests early monetization and potential non-dilutive funding. The Phase 3 EMPEROR study for zorevunersen is critical, with regulatory alignment and promising early data, but execution and long-term safety monitoring remain challenges.
seekingalpha.com
- 1 month ago
Strength Seen in Stoke Therapeutics (STOK): Can Its 9.4% Jump Turn into More Strength?
Stoke Therapeutics (STOK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
zacks.com
- 2 months ago
Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?
Here, we discuss some reasons why investing in STOK now may turn out to be a prudent move.
zacks.com
- 2 months ago
Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that management will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 6:00 p.m. ET (3:00 p.m. PT). A live audio webcast of the presentation will be available on the Investors & News section of Stoke's website at https://investor.stokether.
businesswire.com
- 2 months ago
8. Profile
Summary
Stoke Therapeutics, Inc. STOK
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 321 M
Dividend Yield
0.00%
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Contact
45 Wiggins Avenue, Bedford, MA, 01730
https://www.stoketherapeutics.com
IPO
Date
June 19, 2019
Employees
128
Officers
Mr. Thomas Edward Leggett
Chief Financial Officer
Mr. Jonathan Allan J.D.
Corporate Secretary & General Counsel
Mr. Ian F. Smith A.C.A., C.P.A.
Interim Chief Executive Officer & Director
Mr. Eric Rojas
Vice President & Head of Investor Relations
Ms. Isabel Aznarez Ph.D.
Co-Founder, Head of Research & Senior Vice President
Ms. Dawn Kalmar
Chief Communications Officer
Dr. Arthur O. Tzianabos Ph.D.
Interim Executive Chairman
Dr. Adrian R. Krainer Ph.D.
Co-Founder & Independent Director
Dr. Edward M. Kaye M.D., Ph.D.
Advisor & Director
Dr. Barry S. Ticho FACC, M.D., Ph.D.
Chief Medical Officer